ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
We focus on developing pioneering and novel peptide drugs in specialist therapeutic areas
ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality Bio-pharma company that discovers and develops peptide-based therapeutics. The Company is headquartered in London with its research team, ImmuPharma Biotech, based in Bordeaux, France.
The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus.
Preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action, based on the P140 platform technology.
ImmuPharma and Avion Pharmaceuticals have an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 2/3 adaptive study for Lupuzor™ and commercialise in the US.
4 core lead assets, 2 at late clinical stage
Lupuzor™
Autoimmunity
Lupus
Status
Phase 2/3 adaptive study (pivotal)
Study start
2023/24
P140
Inflammation
CIDP
Status
Phase 2/3 adapative (pivotal)
Study start
2023/24
BioAMB
Anti-infection
Severe Fungal infection
Status
Late pre-clinical
Partnering
2023/24
BioCIN
Anti-infection
Severe Bacterial infection
Status
Late pre-clinical
Partnering
2023/24
Why Invest in ImmuPharma?
- A rich portfolio with 2 highly attractive late-stage clinical indications – Lupus & CIDP (Both entering Phase 2/3 adaptive studies)
- Near-term business development opportunities across all programs
- Innovative peptide platform within P140 targeting a number of exciting autoimmune diseases
Key progress
Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
Phase 2/3 adaptive study design for Lupus study agreed with Avion
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to ...
Market Cap
15 minute delayed share price provided by Hemscott Group Limited Disclaimer
Share Price - more details
Market Commentary
Professional advisers
Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
www.sparkadvisorypartners.com
Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street
London
EC1V 9EE
www.stanfordcp.co.uk/contact-us
Joint Broker
Si Capital Limited
info@sicapital.co.uk
Public Relations & Investor Relations
lisa.baderoon@immupharma.com
Auditors
Evelyn Partners, 45 Gresham St,
London EC2V 7BG
Legal Representatives
BDB Pitmans LLP
London, U.K.
Badertscher Rechtsanwälte AG
Zurich, Switzerland
Accountants & Company Secretary
Ward Williams
Belgrave House, 39-43 Monument Hill,
Weybridge KT13 8RN
Patent Agents
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France
Manufacturers
Under contract with a leading manufacturer in the peptides field